

Appl. No. 09/448,378  
Amdt. dated April 22, 2004  
Response to OA of November 5, 2003

## 2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-5 (Cancelled)

6. (Previously presented) A method for augmenting an immune response in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand to the patient in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient.

7. (Previously presented) A method according to claim 6, further comprising the step of administering one or more of the molecules selected from the group consisting of GM-CSF, IL-4, TNF- $\alpha$ , IL-3, c-kit ligand, and fusions of GM-CSF and IL-3.

8-19 (Cancelled)

20. (Previously presented) A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient in an amount sufficient to enhance the patient's immune response to such disease and administering a tumor antigen to the patient.

21. (Cancelled)

22. (Previously presented) The method of claim 6, wherein the flt3-ligand is human flt3-ligand.

23. (Previously presented) The method of claim 22, wherein the flt3-ligand is soluble human flt3-ligand.

24. (Previously presented) The method of claim 23, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

25. (Withdrawn) The method of claim 24, wherein the soluble human flt3-ligand has an amino acid sequence that is encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to, and is at least 90% identical to, a nucleic acid that encodes an amino acid sequence selected from the group consisting of amino acids 28 to Xaa

Appl. No. 09/448,378  
Amdt. dated April 22, 2004  
Response to OA of November 5, 2003

of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

26. *(Previously presented)* The method of claim 24, wherein the soluble human flt3-ligand comprises an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

27. *(Currently amended)* The method of claim 6, wherein the flt3-ligand comprises has the amino acid sequence of residues 28-163 of SEQ ID NO:2.

28. *(Currently amended)* The method of claim 26, wherein the soluble human flt3-ligand comprises has the amino acid sequence of residues 28-160 of SEQ ID NO:1.

29. *(Currently amended)* The method of claim 6, wherein the flt3-ligand comprises has the amino acid sequence of residues 28-188 of SEQ ID NO:2.

30. *(Currently amended)* The method of claim 26, wherein the soluble human flt3-ligand comprises has the amino acid sequence of residues 28-182 of SEQ ID NO:1.

31. *(Previously presented)* The method of claim 20, wherein the flt3-ligand is human flt3-ligand.

32. *(Previously presented)* The method of claim 31, wherein the flt3-ligand is soluble human flt3-ligand.

33. *(Previously presented)* The method of claim 32, wherein the soluble human flt3-ligand is recombinant flt3-ligand.

34. *(Withdrawn)* The method of claim 33, wherein the soluble human flt3-ligand has an amino acid sequence that is encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to, and is at least 90% identical to, a nucleic acid that encodes an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.

Appl. No. 09/448,378  
Amdt. dated April 22, 2004  
Response to OA of November 5, 2003

35. *(Previously presented)* The method of claim 33, wherein the soluble human flt3-ligand comprises an amino acid sequence selected from the group consisting of amino acids 28 to Xaa of SEQ ID NO:2 and amino acids 28 to Yaa of SEQ ID NO:1, wherein Xaa is an amino acid from 163 to 231, and Yaa is an amino acid from 160 to 235.
36. *(Currently amended)* The method of claim 20, wherein the flt3-ligand comprises has the amino acid sequence of residues 28-163 of SEQ ID NO:2.
37. *(Currently amended)* The method of claim 35, wherein the soluble human flt3-ligand comprises has the amino acid sequence of residues 28-160 of SEQ ID NO:1.
38. *(Currently amended)* The method of claim 20, wherein the flt3-ligand comprises has the amino acid sequence of residues 28-188 of SEQ ID NO:2.
39. *(Currently amended)* The method of claim 35, wherein the soluble human flt3-ligand comprises has the amino acid sequence of residues 28-182 of SEQ ID NO:1.
40. *(Previously presented)* The method of claim 6 wherein the cancerous disease is a tumor.
41. *(Previously presented)* The method of claim 20 wherein the cancerous disease is a tumor.
42. *(Previously presented)* The method of claim 40 wherein the tumor is a fibrosarcoma.
43. *(Previously presented)* The method of claim 41 wherein the tumor is a fibrosarcoma.
44. *(Previously presented)* The method of claim 6, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.
45. *(Previously presented)* The method of claim 6, wherein the tumor antigen is in the form of an isolated tumor antigen.
46. *(Previously presented)* The method of claim 6, wherein the antigen is administered prior to administering flt3-ligand.
47. *(Previously presented)* The method of claim 6, wherein the antigen is administered concurrently with flt3-ligand.

Appl. No. 09/448,378  
Amdt. dated April 22, 2004  
Response to OA of November 5, 2003

48. *(Previously presented)* The method of claim 6, wherein the antigen is administered after administering flt3-ligand.
49. *(Previously presented)* The method of claim 20, wherein the tumor antigen is in the form of a tumor cell bearing said tumor antigen.
50. *(Previously presented)* The method of claim 20, wherein the tumor antigen is in the form of an isolated tumor antigen.
51. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered prior to administering flt3-ligand.
52. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered concurrently with administering flt3-ligand.
53. *(Previously presented)* The method of claim 20, wherein the tumor antigen is administered after administering flt3-ligand.
54. *(Withdrawn)* A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand to the patient, isolating dendritic cells from the patient, exposing the dendritic cells to a tumor antigen, and administering the dendritic cells to the patient.
55. *(Withdrawn)* The method of claim 54, wherein the tumor antigen is in the form of a tumor cell bearing said antigen.
56. *(Withdrawn)* The method of claim 54, wherein the tumor antigen is in the form of an isolated tumor antigen.